ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.9907
0.28%
Brent Oil
83.56
0.02%
Bitcoin
58,897.81
1.13%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Chemomab Therapeutics Ltd (CMMB)

  7. Chemomab Therapeutics Ltd (CMMB) Noticias

CMMB

Chemomab Therapeutics (CMMB)

Chemomab Therapeutics Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CMMB
FechaHoraFuenteTítuloSímboloCompañía
02/05/202406:00GlobeNewswire Inc.Chemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
24/04/202406:00GlobeNewswire Inc.Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
18/04/202406:00GlobeNewswire Inc.Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
02/04/202406:00GlobeNewswire Inc.Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024NASDAQ:CMMBChemomab Therapeutics Ltd
25/03/202406:06GlobeNewswire Inc.Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
07/03/202406:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
07/03/202406:00PR Newswire (US)Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/03/202406:00PR Newswire (US)Chemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
20/02/202408:20AllPennyStocks.comBiotech Shares Massively Bid Up Before Opening BellNASDAQ:CMMBChemomab Therapeutics Ltd
20/02/202406:00PR Newswire (US)Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesNASDAQ:CMMBChemomab Therapeutics Ltd
14/02/202406:00PR Newswire (US)Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/02/202406:00PR Newswire (US)Chemomab Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
30/01/202406:00PR Newswire (US)Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
03/01/202406:00PR Newswire (US)Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024NASDAQ:CMMBChemomab Therapeutics Ltd
16/11/202306:00PR Newswire (US)Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
15/11/202315:35Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
15/11/202306:00PR Newswire (US)Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
13/11/202307:00PR Newswire (US)Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023NASDAQ:CMMBChemomab Therapeutics Ltd
09/11/202307:00PR Newswire (US)Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
06/11/202315:15PR Newswire (US)Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price RequirementNASDAQ:CMMBChemomab Therapeutics Ltd
05/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMMBChemomab Therapeutics Ltd
30/10/202307:33Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
30/10/202306:00PR Newswire (US)Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
26/10/202306:00PR Newswire (US)Chemomab Therapeutics to Present at Upcoming Scientific ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
16/10/202315:25Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CMMBChemomab Therapeutics Ltd
28/09/202306:00PR Newswire (US)Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
29/08/202306:00PR Newswire (US)Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
14/08/202307:00PR Newswire (US)Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/07/202316:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMMBChemomab Therapeutics Ltd
28/06/202306:00PR Newswire (US)Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CMMB

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
PM
XAUUSD
Gold vs US Dollar
CCOM
US500
US 500
USOTC
ADDYY
Adidas (QX)
AMEX
XLV
Health Care Select Sector
COIN
SOLUSD
Solana
AMEX
XLE
Energy Select Sector SPDR
FX
USDMXN
US Dollar vs MXN
COIN
BTCUSD
Bitcoin
CCOM
SILVER
SILVER
NYSE
MCD
McDonalds
NYSE
AXP
American Express
COIN
ETHUSD
Ethereum
NASDAQ
TSLA
Tesla
USI
USTECH100
US Tech 100
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados